Company Overview

Oaktree Acquisition Corp. III Life Sciences (ticker: OACC) is a special purpose acquisition company (SPAC) formed to pursue a business combination with a target operating company in the life sciences and healthcare sectors. The company does not have commercial operations of its own and was created for the purpose of identifying, acquiring, or merging with a business that can benefit from public market access and long-term strategic capital.

OACC is sponsored by affiliates of Oaktree Capital Management, a global alternative investment manager known for its expertise in credit, private equity, and real assets. The SPAC structure allows OACC to raise capital through an initial public offering and hold those proceeds in trust while management evaluates potential acquisition candidates. As of the most recent public filings, OACC has not completed a business combination, and its activities are limited to target evaluation, regulatory compliance, and capital preservation.

Business Operations

OACC’s operations are limited to SPAC-related activities, including maintaining its trust account, conducting due diligence on potential acquisition targets, and managing legal, financial, and regulatory obligations. The company generates no operating revenue, and substantially all assets consist of cash and short-term U.S. government securities held in trust for the benefit of public shareholders.

The company’s investment mandate is focused on life sciences opportunities, including but not limited to biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. OACC does not control operating technologies, products, or services, and it has no subsidiaries or joint ventures beyond standard SPAC-related corporate entities. Any future operating business would arise only upon the successful completion of a merger or similar transaction.

Strategic Position & Investments

Strategically, OACC is positioned to leverage the life sciences investing experience, industry relationships, and capital markets expertise of Oaktree Capital Management. The sponsor’s background in structured investments and long-duration capital is intended to support transactions involving complex scientific, regulatory, or capital structures common in the life sciences sector.

As of available public disclosures, OACC has not announced or completed any acquisitions, investments, or definitive merger agreements. Its strategic focus remains on identifying a single, high-quality life sciences company with scalable growth potential and a defensible competitive position. Data inconclusive based on available public sources regarding specific target criteria beyond the general sector focus.

Geographic Footprint

OACC is incorporated in the United States and is headquartered in North America, with administrative operations centered in the U.S. Its geographic footprint is currently limited, as the company does not operate physical facilities or conduct commercial activities.

The company’s investment mandate is not geographically restricted, and it may pursue a target with operations in North America, Europe, or other global life sciences hubs. Any international operational presence would depend entirely on the location and scope of the future acquisition target.

Leadership & Governance

OACC is led by an executive team affiliated with Oaktree Capital Management, bringing experience in alternative investments, public markets, and corporate governance. The leadership team is responsible for sourcing acquisition opportunities, overseeing due diligence, and executing a business combination in the best interests of shareholders.

Key executives and directors publicly associated with OACC include:

• Glenn August – Chief Executive Officer
• Armen Panossian – President
• Howard Marks – Co-Founder, Oaktree Capital Management (non-executive sponsor affiliation)
• Bruce Karsh – Co-Founder, Oaktree Capital Management (non-executive sponsor affiliation)

The leadership philosophy emphasizes disciplined capital allocation, risk management, and long-term value creation. Data inconclusive based on available public sources regarding additional executive officers beyond those disclosed in regulatory filings and offering documents.